Pemigatinib Approved for Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement

The FDA has approved pemigatinib (Pemazyre®, Incyte Corporation) for the treatment of relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with a fibroblast growth factor receptor 1 (FGFR1) rearrangement. This is the first approval and only targeted treatment for MLNs with a FGFR1 rearrangement. "Myeloid/lymphoid neoplasms with a FGFR1 rearrangement comprise rare hematologic neoplasms belonging to the World Health Organization major category of fusion tyrosine kinases typically associated wi...

Continue reading

Copyright ┬ę 2022 Oncology Data Advisor. All rights reserved.